Y-mAbs Therapeutics' (YMAB) Neutral Rating Reaffirmed at HC Wainwright

Key Points

• HC Wainwright has reiterated a "neutral" rating for Y-mAbs Therapeutics, lowering the target price from $11.00 to $8.60, suggesting minimal potential upside of 0.94%.
• Y-mAbs Therapeutics has received a consensus rating of "Hold" from analysts, with two sell ratings, six hold ratings, two buy ratings, and two strong buy ratings issued.
• The company's stock has significantly increased, up 103.3%, and its 52-week price range is $3.55 to $16.11.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report)'s stock had its "neutral" rating reissued by HC Wainwright in a research report issued to clients and investors on Wednesday, August 6th, MarketBeat Ratings reports. They currently have a $8.60 price objective on the stock, down from their previous price objective of $11.00. HC Wainwright's price target points to a potential upside of 1.06% from the stock's previous close.

Several other analysts have also recently commented on YMAB. Bank of America cut shares of Y-mAbs Therapeutics from a "neutral" rating to an "underperform" rating and set a $3.00 target price for the company. in a research note on Tuesday, April 22nd. Jones Trading lowered shares of Y-mAbs Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 5th. Truist Financial set a $8.60 price target on shares of Y-mAbs Therapeutics in a report on Tuesday, August 5th. Oppenheimer lowered shares of Y-mAbs Therapeutics from an "outperform" rating to a "market perform" rating in a report on Tuesday, August 5th. Finally, Morgan Stanley set a $8.60 price target on shares of Y-mAbs Therapeutics in a report on Tuesday, August 5th. Two analysts have rated the stock with a sell rating, eight have given a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $11.16.

Y-mAbs Therapeutics Stock Performance

YMAB stock remained flat at $8.51 on Wednesday. The company had a trading volume of 651,513 shares, compared to its average volume of 483,366. Y-mAbs Therapeutics has a 12-month low of $3.55 and a 12-month high of $16.11. The firm's 50-day moving average price is $5.09 and its two-hundred day moving average price is $4.97. The company has a market capitalization of $386.68 million, a P/E ratio of -17.02 and a beta of 0.57.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last posted its earnings results on Friday, August 8th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.27) by $0.20. The firm had revenue of $19.52 million for the quarter, compared to analyst estimates of $18.40 million. Y-mAbs Therapeutics had a negative return on equity of 24.60% and a negative net margin of 26.03%. As a group, equities analysts anticipate that Y-mAbs Therapeutics will post -0.65 EPS for the current year.

Hedge Funds Weigh In On Y-mAbs Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Brooklyn Investment Group lifted its holdings in Y-mAbs Therapeutics by 4,563.8% in the 1st quarter. Brooklyn Investment Group now owns 5,923 shares of the company's stock worth $26,000 after buying an additional 5,796 shares in the last quarter. CWM LLC lifted its holdings in Y-mAbs Therapeutics by 203.0% in the 2nd quarter. CWM LLC now owns 7,121 shares of the company's stock worth $32,000 after buying an additional 4,771 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in Y-mAbs Therapeutics in the 4th quarter worth $46,000. Los Angeles Capital Management LLC acquired a new position in Y-mAbs Therapeutics in the 2nd quarter worth $46,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in Y-mAbs Therapeutics in the 1st quarter worth $49,000. Institutional investors and hedge funds own 70.85% of the company's stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.